REDWOOD CITY, Calif.,
Feb. 22, 2018 /PRNewswire/
-- Nevro Corp. (NYSE: NVRO), a global medical device company
that is providing innovative evidence-based solutions for the
treatment of chronic pain, today reported financial results for the
three months and full year ended December
31, 2017.
2017 Accomplishment & Highlights:
- Achieved revenue of $326.7
million for the full year 2017, an increase of 43%, as
reported, over the prior year
-
- U.S. revenue of $263.5 million
for 2017, an increase of 52% over the prior year
- International revenue of $63.2
million for 2017, an increase of 13% in constant currency
and 15% on an as-reported basis, both over the prior year
- Achieved positive EBITDA and operating cash flow for each of
the third and fourth quarters of 2017, excluding litigation
expense
- Received CE Mark for next generation Senza II
- Received CE Mark for Senza I Conditional Full Body MRI
- Initiated Randomized Controlled Trials (RCT) in two new
indications
- Presented positive clinical trial results during the
16th Annual Pain Medicine Meeting, 2017:
-
- Demonstrated an approximate 78% reduction in VAS pain score in
neck and an approximate 86% reduction in VAS pain score in upper
limb at twelve-months for interim data from SENZA-ULN, a
prospective, multicenter clinical trial evaluating HF10 therapy for
the treatment of chronic intractable neck and/or upper limb
pain
- Demonstrated an approximate 75% reduction in VAS pain score at
three-months for interim data from SENZA-PPN, a prospective,
multicenter clinical trial evaluating HF10 therapy for the
treatment of peripheral polyneuropathy, which led to the initiation
of a large-scale randomized trial for painful diabetic neuropathy
(SENZA-PDN)
- Demonstrated an approximate 70% reduction in VAS pain score at
three-months for interim data from a multicenter feasibility study
evaluating HF10 therapy for the treatment of chronic abdominal
pain
- Selected by Neurosurgery, the official journal of the
Congress of Neurological Surgeons (CNS), as Top Pain Paper of the
Year for the SENZA-RCT 24-month outcomes publication
Fourth Quarter Financial Results
Revenue for the quarter ended December
31, 2017 was $98.0 million
versus $70.5 million during the same
period of the prior year, representing 39% growth as reported. U.S.
revenue for the three months ended December
31, 2017 was $81.1 million,
representing 45% growth as reported. International revenue was
$16.9 million, representing growth of
10% in constant currency and 17% on an as-reported basis. The
increase in revenue was primarily attributable to the continued
adoption of the Senza system.
Gross profit for the fourth quarter of 2017 was $69.5 million, representing a 71% gross margin,
up from $48.8 million, representing a
69% gross margin, in the same period of the prior year.
Operating expenses for the fourth quarter of 2017 were
$71.7 million compared to
$55.1 million in the same period of
the prior year, representing an increase of 30%. The increase in
operating expenses was driven primarily by increased headcount and
related personnel costs, as well as legal expenses associated with
intellectual property litigations.
Loss from operations for the fourth quarter of 2017 was
$2.2 million compared to $6.3 million for the same period of the prior
year.
Revenue Guidance for Full Year 2018
Nevro reiterates worldwide revenue for 2018 to be in the range
of $400.0 to $410.0 million, which was first announced in
January 2018.
Webcast and Conference Call Information
Management will host a conference call today beginning at
1:30 p.m. PT / 4:30 p.m. ET. Individuals interested in listening
to the conference call may dial (866) 393-4306 for domestic
callers, or (734) 385-2616 for international callers (Conference
ID: 2584428), or access the webcast on the "Investors" section of
the company's web site at: www.nevro.com/investors.
About Nevro
Headquartered in Redwood City,
California, Nevro is a global medical device company focused
on providing innovative products that improve the quality of life
of patients suffering from debilitating chronic pain. Nevro has
developed and commercialized the SENZA® spinal cord stimulation
(SCS) system, an evidence-based, non-pharmacologic neuromodulation
platform for the treatment of chronic pain. The SENZA® system is
the only SCS system that delivers Nevro's proprietary HF10™
therapy. Senza, Senza II, HF10, Nevro and the Nevro logo are
trademarks of Nevro.
Forward-Looking Statements
In addition to historical information, this press release
contains forward-looking statements with respect to our business,
capital resources, revenue projections, strategic initiatives and
growth, reflecting the current beliefs and expectations of
management made pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995, including
continuing adoption of, and interest in, Senza in the U.S. and
international markets; and our expectations for worldwide revenue
for the full year 2018. These forward-looking statements are based
upon information that is currently available to us or our current
expectations, speak only as of the date hereof, and are subject to
numerous risks and uncertainties, including our ability to
successfully commercialize our products; our ability to manufacture
our products to meet demand; the level and availability of
third-party payor reimbursement for our products; our ability to
effectively manage our anticipated growth; our ability to protect
our intellectual property rights and proprietary technologies; our
ability to operate our business without infringing the intellectual
property rights and proprietary technology of third parties;
competition in our industry; additional capital and credit
availability; our ability to attract and retain qualified
personnel; and product liability claims. These factors, together
with those that are described in greater detail in our Annual
Report on Form 10-K that we expect to file on February 22, 2018, as well as any reports that we
may file with the SEC in the future, may cause our actual results,
performance or achievements to differ materially and adversely from
those anticipated or implied by our forward-looking statements. We
expressly disclaim any obligation, except as required by law, or
undertaking to update or revise any such forward-looking
statements. Our results for the full year and quarter ended
December 31, 2017 are not necessarily
indicative of our operating results for any future periods.
Investor Relations Contact:
Nevro Investor
Relations
Katherine Bock
(650) 433-3247
ir@nevro.com
Nevro
Corp. Consolidated Statements of Operations and
Comprehensive Loss (in thousands, except share and per
share data)
|
|
|
|
Three Months
Ended
|
|
|
Year
Ended
|
|
|
|
December 31,
|
|
|
December 31,
|
|
|
|
2017
|
|
|
2016
|
|
|
2017
|
|
|
2016
|
|
|
|
(unaudited)
|
|
|
|
|
|
|
|
|
|
Revenue
|
|
$
|
97,963
|
|
|
$
|
70,531
|
|
|
$
|
326,674
|
|
|
$
|
228,504
|
|
Cost of
revenue
|
|
|
28,451
|
|
|
|
21,692
|
|
|
|
98,981
|
|
|
|
75,433
|
|
Gross
profit
|
|
|
69,512
|
|
|
|
48,839
|
|
|
|
227,693
|
|
|
|
153,071
|
|
Operating
expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and
development
|
|
|
9,943
|
|
|
|
11,276
|
|
|
|
37,560
|
|
|
|
33,729
|
|
Sales, general and
administrative
|
|
|
61,741
|
|
|
|
43,832
|
|
|
|
219,712
|
|
|
|
142,423
|
|
Total operating
expenses
|
|
|
71,684
|
|
|
|
55,108
|
|
|
|
257,272
|
|
|
|
176,152
|
|
Loss from
operations
|
|
|
(2,172)
|
|
|
|
(6,269)
|
|
|
|
(29,579)
|
|
|
|
(23,081)
|
|
Other income
(expense):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest income
(expense), net
|
|
|
(1,616)
|
|
|
|
(1,780)
|
|
|
|
(6,738)
|
|
|
|
(4,709)
|
|
Other income
(expense), net
|
|
|
(131)
|
|
|
|
(1,193)
|
|
|
|
1,067
|
|
|
|
(1,097)
|
|
Loss on extinguishment
of debt
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
(1,268)
|
|
Loss before income
taxes
|
|
|
(3,919)
|
|
|
|
(9,242)
|
|
|
|
(35,250)
|
|
|
|
(30,155)
|
|
Provision for income
taxes
|
|
|
392
|
|
|
|
583
|
|
|
|
1,408
|
|
|
|
1,623
|
|
Net loss
|
|
|
(4,311)
|
|
|
|
(9,825)
|
|
|
|
(36,658)
|
|
|
|
(31,778)
|
|
Changes in foreign
currency translation
adjustment
|
|
|
(319)
|
|
|
|
283
|
|
|
|
(360)
|
|
|
|
(163)
|
|
Changes in gains
(losses) on short-term
investments
|
|
|
(311)
|
|
|
|
(44)
|
|
|
|
(204)
|
|
|
|
(340)
|
|
Net change in other
comprehensive loss
|
|
|
(630)
|
|
|
|
239
|
|
|
|
(564)
|
|
|
|
(503)
|
|
Comprehensive
Loss
|
|
$
|
(4,941)
|
|
|
$
|
(9,586)
|
|
|
$
|
(37,222)
|
|
|
$
|
(32,281)
|
|
Net loss per share,
basic and diluted
|
|
$
|
(0.15)
|
|
|
$
|
(0.34)
|
|
|
$
|
(1.25)
|
|
|
$
|
(1.12)
|
|
Weighted average
shares used to compute
net
loss per share, basic and diluted
|
|
|
29,664,926
|
|
|
|
28,817,333
|
|
|
|
29,424,054
|
|
|
|
28,485,003
|
|
Nevro
Corp. Consolidated Balance Sheets (in
thousands, except share and per share data)
|
|
|
|
December 31,
|
|
|
December 31,
|
|
|
|
2017
|
|
|
2016
|
|
|
|
|
|
|
|
|
|
|
Assets
|
|
|
|
|
|
|
|
|
Current
assets
|
|
|
|
|
|
|
|
|
Cash and cash
equivalents
|
|
$
|
42,845
|
|
|
$
|
41,406
|
|
Short-term
investments
|
|
|
226,467
|
|
|
|
234,951
|
|
Accounts receivable,
net
|
|
|
67,287
|
|
|
|
52,818
|
|
Inventories,
net
|
|
|
98,119
|
|
|
|
85,221
|
|
Prepaid expenses and
other current assets
|
|
|
6,463
|
|
|
|
5,895
|
|
Total current
assets
|
|
|
441,181
|
|
|
|
420,291
|
|
Property and
equipment, net
|
|
|
8,819
|
|
|
|
7,132
|
|
Other
assets
|
|
|
3,250
|
|
|
|
2,354
|
|
Restricted
cash
|
|
|
806
|
|
|
|
806
|
|
Total
assets
|
|
$
|
454,056
|
|
|
$
|
430,583
|
|
Liabilities and
stockholders' equity
|
|
|
|
|
|
|
|
|
Current
liabilities
|
|
|
|
|
|
|
|
|
Accounts
payable
|
|
$
|
18,492
|
|
|
$
|
16,162
|
|
Accrued liabilities
and other
|
|
|
39,512
|
|
|
|
26,036
|
|
Total current
liabilities
|
|
|
58,004
|
|
|
|
42,198
|
|
Long-term
debt
|
|
|
145,019
|
|
|
|
138,140
|
|
Other long-term
liabilities
|
|
|
1,861
|
|
|
|
1,211
|
|
Total
liabilities
|
|
|
204,884
|
|
|
|
181,549
|
|
Stockholders'
equity
|
|
|
|
|
|
|
|
|
Common stock, $0.001
par value, 290,000,000 shares authorized,
29,737,561 and 28,886,862 shares issued and
outstanding at
December 31, 2017 and 2016, respectively
|
|
|
30
|
|
|
|
29
|
|
Additional paid-in
capital
|
|
|
508,228
|
|
|
|
470,869
|
|
Accumulated other
comprehensive loss
|
|
|
(1,242)
|
|
|
|
(678)
|
|
Accumulated
deficit
|
|
|
(257,844)
|
|
|
|
(221,186)
|
|
Total stockholders'
equity
|
|
|
249,172
|
|
|
|
249,034
|
|
Total liabilities and
stockholders' equity
|
|
$
|
454,056
|
|
|
$
|
430,583
|
|
View original content with
multimedia:http://www.prnewswire.com/news-releases/nevro-reports-fourth-quarter-and-full-year-2017-financial-results-and-provides-2018-outlook-300603005.html
SOURCE Nevro Corp.